What changed in Exelixis Inc's latest annual report
In the year ended 2 Jan 2026, Exelixis Inc's revenue rose 7% to USD 2.32bn, from USD 2.17bn; net income rose 50.1% to USD 782.57m, from USD 521.27m; cash and cash equivalents rose 122% to USD 482.49m, from USD 217.37m.
Year ended 2 Jan 2026. Source: 10-K filed 10 Feb 2026, read it on SEC EDGAR.
USD 2.17bn to USD 2.32bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.17bn | 2.32bn | Up 7% |
| Net income | 521.27m | 782.57m | Up 50.1% |
| Total assets | 2.95bn | 2.84bn | Down 3.5% |
| Total liabilities | 703.49m | 683.10m | Down 2.9% |
| Cash and cash equivalents | 217.37m | 482.49m | Up 122% |
| Shareholders' equity | 2.24bn | 2.16bn | Down 3.7% |
Questions people ask
Did Exelixis Inc's revenue grow last year?
Revenue grew 7%, from USD 2.17bn to USD 2.32bn in the year ended 2 Jan 2026.
Is Exelixis Inc profitable?
Yes. Net income was USD 782.57m in the year ended 2 Jan 2026. The year before: USD 521.27m.
How much cash and debt does Exelixis Inc have?
At its latest year end (2 Jan 2026), Exelixis Inc reported cash and cash equivalents of USD 482.49m.
Where do these numbers come from?
From Exelixis Inc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Exelixis Inc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%